Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Keywords/Phrases:  hormone therapy
Results 1-25 of 3289 for your search:
Start Over
Enzalutamide, Radiation Therapy, and Hormone Therapy in Treating Patients with Intermediate- or High-Risk Prostate Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 13P.461, NCI-2013-02283, 080-38340-J90801, 2013-027, 2970, NCT02023463
Abiraterone Acetate, Radiation Therapy, and Hormone Therapy in Treating Patients with Unfavorable-Risk Localized Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 20 to 80
Trial IDs: Pro00044071, NCI-2013-01803, NCT01717053
Radiation Therapy, Hormone Therapy, and Docetaxel in Treating Patients with High-Risk Prostate Cancer Previously Treated with Surgery
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 85
Trial IDs: 12313, NCI-2011-01380, 4P-06-3, CR00001450, HS-08-00201, NCT00669162
Cabazitaxel, Intensity-Modulated Radiation Therapy, and Hormone Therapy in Treating Patients with Locally Advanced High-Risk Prostate Cancer
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 11D.243, NCI-2011-02420, 2011-32, NCT01420250
Intensity Modulated Radiation Therapy with Stereotactic Radiosurgery Boost and Hormone Therapy in Treating Patients with Prostate Cancer
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: CCRO025, NCI-2014-01486, 421870, NCT02064036
Stereotactic Body Radiation Therapy and Hormone Therapy in Treating Patients with Localized Intermediate-Risk Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: J11157, NCI-2013-01332, CIR00008893, NA_00067963, NA_00067963/CIR00003978, NCT01517451
Hormone Therapy and Ipilimumab in Treating Patients with Advanced Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MC0253, NCI-2009-01214, NCT00170157
Hormone Therapy with or without Everolimus in Treating Patients with Breast Cancer
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: S1207, NCI-2012-01995, CDR0000738280, SWOG-S1207, NCT01674140
LHRH Analogue Therapy with Enzalutamide or Bicalutamide in Treating Patients with Metastatic Hormone Sensitive Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-083, NCI-2014-00212, 1311012529, NCT02058706
Radium Ra 223 Dichloride, Hormone Therapy, and Denosumab in Treating Patients with Hormone-Positive, Bone-Dominant Metastatic Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0508, NCI-2015-00508, NCT02366130
Androgen Deprivation Therapy, Enzalutamide, and Radiation Therapy in Treating Patients with Recurrent Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00049865, NCI-2014-01161, DUMC Pro00049865, NCT02057939
Androgen Deprivation Therapy with or without Palbociclib Isethionate in Treating Patients with RB-Positive Metastatic Hormone-Sensitive Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: UMCC 2013.117, NCI-2014-01922, HUM00082715, NCT02059213
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CR103305, NCI-2013-01912, ARN-509-002, NCT01790126
Zoptarelin Doxorubicin in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: 4P-09-9, NCI-2009-01418, NCT01240629
Trastuzumab and Pertuzumab Alone or in Combination With Hormone Therapy or Eribulin Mesylate in Treating Older Patients With Stage IIIB-IV HER2-Positive Breast Cancer
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: GCC1303, NCI-2014-00874, 1303GCC, ML28192, NCT02000596
Cabozantinib-S-Malate and Hormone Therapy in Treating Patients with Previously Untreated Androgen-Dependent Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Age: Not specified
Trial IDs: 2012-0252, NCI-2014-00934, NCI-2014-00158, NCT01630590
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients with Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0924, NCI-2011-02674, CDR0000701128, PRTOG-0924_A03PAMDREVW01, NCT01368588
Exemestane with or without Entinostat in Treating Postmenopausal Patients with Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E2112, NCI-2014-00746, ECOG-E2112, NCT02115282
Radiation Therapy with or without Androgen-Deprivation Therapy in Treating Patients with Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: RTOG 0815, NCI-2011-01948, CDR0000648194, NCT00936390
Androgen Deprivation Therapy and Orteronel or Bicalutamide in Treating Patients with Newly Diagnosed Metastatic Prostate Cancer
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: S1216, NCI-2012-02876, SWOG-S1216, NCT01809691
Enzalutamide in Treating Patients with Advanced or Recurrent Androgen Receptor-Positive Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13-119, NCI-2013-02217, NCT01974765
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: MDV3100-13, NCI-2015-00824, NCT02319837
Start Over